Navigation Links
PDL BioPharma Announces Conversion Rate Adjustments for 2.00% Convertible Senior Notes Due February 15, 2012 and 2.875% Convertible Senior Notes Due February 15, 2015
Date:3/8/2011

INCLINE VILLAGE, Nev., March 8, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced an adjustment to the conversion rate for its 2.00% Convertible Senior Notes due February 15, 2012 (the 2012 Notes) and its 2.875% Convertible Senior Notes due February 15, 2015 (the 2015 Notes) effective March 7, 2011, in connection with the regular dividend to be paid on March 15, 2011, to all stockholders who own shares of PDL on March 8, 2011, the record date.

The conversion rate for the 2012 Notes and the 2015 Notes, as adjusted, is 144.474 shares of common stock per $1,000 principal amount or $6.92 per share. The conversion rate for the 2012 Notes and the 2015 Notes was previously 140.571 shares of common stock per $1,000 principal amount of the 2012 Notes and the 2015 Notes. In connection with a cash dividend, the conversion rate is increased by multiplying the previous conversion rate by a fraction, the numerator of which is the average closing price of PDL's common stock for the five consecutive trading days immediately preceding the ex-dividend date of March 4, 2011, for the cash dividend, and the denominator of which is the difference of such average closing price less the dividend amount.

About PDL BioPharma

PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The Company receives royalties on sales of a number of humanized antibody products marketed today and also may receive royalty payments on additional humanized antibody products launched before patent expiry in late 2014. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

Forward-looking Statements

The foregoing statements regarding PDL's intentions with respect to the quarterly dividend payment described above are forward-looking statements under the Private Securities Litigation Reform Act of 1995, and actual results could vary materially from the statements made. PDL's ability to pay the dividend described above is subject to various risks, many of which are outside its control, including prevailing conditions in the capital markets, the continued strength of its royalty assets and other risks and uncertainties as detailed from time to time in the reports filed by PDL with the Securities and Exchange Commission.


'/>"/>
SOURCE PDL BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year End 2010 Financial Results on Wednesday, March 9, 2011 at 8:30 a.m. ET
2. Keryx Biopharmaceuticals Announces Oral Presentation of Final Zerenex™ Short-Term Phase 3 Data at the Upcoming National Kidney Foundations 2011 Spring Clinical Meetings
3. Genesis Biopharma Names Marvin S. Hausman M.D. as Chief Science Officer
4. PDL BioPharma Provides First Quarter 2011 Revenue Guidance of $83 Million
5. PDL BioPharma Announces Fourth Quarter and Full Year 2010 Financial Results
6. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
7. PDL BioPharma Announces European Patent Office Determination of Validity of PDLs European Patent is Final
8. PDL BioPharma Announces Regular Quarterly Dividend Policy
9. PDL BioPharma to Present at Upcoming Conferences
10. Enox Biopharma, Inc. to Present at IN3 West Investment in Innovation Conference.
11. Success Factors and Failure Points in Biopharmaceutical Product Launches
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... , Jan. 23, 2017  Therabron Therapeutics, ... a new standard in respiratory care, today announced ... Orphan Medicinal Products has granted Orphan Drug Designation ... of Bronchiolitis Obliterans Syndrome (BOS).  "We ... from the EMA to treat patients diagnosed with ...
(Date:1/23/2017)... , Jan. 23, 2017 Research and ... Market - Forecast to 2021" report to their offering. ... The interventional radiology ... from USD 6.35 Billion in 2016, at a CAGR of 4.8%. ... The major factors driving the growth of this market ...
(Date:1/23/2017)... 2017 Direct-to-consumer digital ... sold and 65% increase in consumable sales, quarter-over-quarter ... (NASDAQ: DRIO ), a leader in digital ... the Dario™ Blood Glucose Monitoring System, an all-in-one diabetes ... app-based and minimally invasive smart diabetes management solution. ...
Breaking Medicine Technology:
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... ... education and high-level training standards for healthcare treatment providers who treat the full ... its Presidents Council. , The Presidents Council consists of the leading eating ...
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... ... University is taught by healthcare management and evaluation leaders with decades of experience ... to pay-for-value in the United States healthcare system, there is a renewed demand ...
(Date:1/23/2017)... ... January 23, 2017 , ... The ... America for the scientific development, healthcare training and clinical application of medical infrared ... 2017 AAT Member Certification Qualification Courses for Technicians, respectively. , For the first ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... Crystallization in Process Chemistry by Applying Simple PAT Tools . , ... to isolate and purify the desired product. Chemists now spend more time ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... earned organic certification under the USDA National Organic Program (NOP) for its Portland ... we have established organic production and handling systems to complement our current rigorous ...
Breaking Medicine News(10 mins):